These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38997548)

  • 1. Establishing Virtual Bioequivalence and Clinically Relevant Specifications for Omeprazole Enteric-Coated Capsules by Incorporating Dissolution Data in PBPK Modeling.
    Yang R; Lin Y; Chen K; Huang J; Yang S; Yao A; Yang X; Lei D; Xiao J; Yang G; Pei Q
    AAPS J; 2024 Jul; 26(4):82. PubMed ID: 38997548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
    Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
    Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space.
    Wang M; Heimbach T; Zhu W; Wu D; Reuter KG; Kesisoglou F
    AAPS J; 2024 Jun; 26(4):69. PubMed ID: 38862807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro In Vivo Extrapolation and Bioequivalence Prediction for Immediate-Release Capsules of Cefadroxil Based on a Physiologically-Based Pharmacokinetic ACAT Model.
    Rahim N; Naqvi SBS
    AAPS PharmSciTech; 2024 May; 25(5):100. PubMed ID: 38714602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs.
    Wu D; Sanghavi M; Kollipara S; Ahmed T; Saini AK; Heimbach T
    Pharm Res; 2023 Feb; 40(2):337-357. PubMed ID: 35840856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers.
    Rhim SY; Park JH; Park YS; Lee MH; Hwang KG; Kim YS; Shaw LM; Lee YS; Kang JS
    Int J Clin Pharmacol Ther; 2009 Jan; 47(1):23-9. PubMed ID: 19203529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico prediction of bioequivalence of Isosorbide Mononitrate tablets with different dissolution profiles using PBPK modeling and simulation.
    Zhang F; Zhou Y; Wu N; Jia R; Liu A; Liu B; Zhou Z; Hu H; Han Z; Ye X; Ding Y; He Q; Wang H
    Eur J Pharm Sci; 2021 Feb; 157():105618. PubMed ID: 33122011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Elevated pH on the Commercial Enteric-Coated Omeprazole Pellets Resistance: Patent Review and Multisource Generics Comparison.
    Mohylyuk V; Yerkhova A; Katynska M; Sirko V; Patel K
    AAPS PharmSciTech; 2021 Jun; 22(5):188. PubMed ID: 34159427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro-In vivo Relationship and Bioequivalence Prediction for Modified-Release Capsules Based on a PBPK Absorption Model.
    Jereb R; Opara J; Legen I; Petek B; Grabnar-Peklar D
    AAPS PharmSciTech; 2019 Dec; 21(1):18. PubMed ID: 31820131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Semi-Mechanistic Physiologically Based Biopharmaceutics Model to Describe Complex and Saturable Absorption of Metformin: Justification of Dissolution Specifications for Extended Release Formulation.
    Bhattiprolu AK; Kollipara S; Boddu R; Arumugam A; Khan SM; Ahmed T
    AAPS PharmSciTech; 2024 Aug; 25(7):193. PubMed ID: 39168956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets.
    Jaiswal S; Ahmed T; Kollipara S; Bhargava M; Chachad S
    Drug Dev Ind Pharm; 2021 May; 47(5):778-789. PubMed ID: 34082622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study.
    Islam MS; Trini AB; Shohag H; Ahmed MU; Maruf AA; Hasnat A
    Int J Clin Pharmacol Ther; 2011 Dec; 49(12):778-86. PubMed ID: 22122821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic omeprazole delayed-release capsules: in vitro performance evaluations.
    Moore T; Smith A; Ye W; Toler DY; Westenberger BJ; Lionberger R; Raw A; Yu L; Buhse LF
    Drug Dev Ind Pharm; 2009 Aug; 35(8):917-21. PubMed ID: 19555236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model.
    Saadeddin A; Purohit V; Huh Y; Wong M; Maulny A; Dowty ME; Sagawa K
    AAPS J; 2024 Jan; 26(1):17. PubMed ID: 38267790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption.
    Laisney M; Heimbach T; Mueller-Zsigmondy M; Blumenstein L; Costa R; Ji Y
    J Pharm Sci; 2022 Jan; 111(1):274-284. PubMed ID: 34678270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient drug development of oseltamivir capsules based on process control, bioequivalence and PBPK modeling.
    Medeiros JJS; Costa TM; Carmo MP; Nascimento DD; Lauro ENC; Oliveira CA; Duque MD; Prado LD
    Drug Dev Ind Pharm; 2022 Apr; 48(4):146-157. PubMed ID: 35876070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.
    Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S
    J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of comparative bioavailability of omeprazole pellets.
    Karim S; Hay YK; Baie SH; Bukhari NI; Murtaza G
    Acta Pol Pharm; 2014; 71(3):463-8. PubMed ID: 25265826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, Bioequivalence, and Safety Studies of Pantoprazole Sodium Enteric-Coated Tablets in Healthy Subjects.
    Chen Z; Gan F; Rao X; Huang X; Chen H
    Clin Pharmacol Drug Dev; 2021 May; 10(5):502-509. PubMed ID: 33128847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Justification of Biowaiver and Dissolution Rate Specifications for Piroxicam Immediate Release Products Based on Physiologically Based Pharmacokinetic Modeling: An In-Depth Analysis.
    Li X; Yang Y; Zhang Y; Wu C; Jiang Q; Wang W; Li H; Li J; Luo C; Wu W; Wang Y; Zhang T
    Mol Pharm; 2019 Sep; 16(9):3780-3790. PubMed ID: 31398041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.